



# LUND UNIVERSITY

## Direct Reprogramming of Human Fetal- and Stem Cell-Derived Glial Progenitor Cells into Midbrain Dopaminergic Neurons

Nolbrant, Sara; Giacomoni, Jessica; Hoban, Deirdre; Bruzelius, Andreas; Birtele, Marcella; Chandler-Militello, Devin; Pereira, Maria; Ottosson, Daniella Rylander; Goldman, Steven A.; Parmar, Malin

*Published in:*  
Stem Cell Reports

*DOI:*  
[10.1016/j.stemcr.2020.08.013](https://doi.org/10.1016/j.stemcr.2020.08.013)

2020

*Document Version:*  
Publisher's PDF, also known as Version of record

[Link to publication](#)

*Citation for published version (APA):*  
Nolbrant, S., Giacomoni, J., Hoban, D., Bruzelius, A., Birtele, M., Chandler-Militello, D., Pereira, M., Ottosson, D. R., Goldman, S. A., & Parmar, M. (2020). Direct Reprogramming of Human Fetal- and Stem Cell-Derived Glial Progenitor Cells into Midbrain Dopaminergic Neurons. *Stem Cell Reports*, 15(4), 869-882.  
<https://doi.org/10.1016/j.stemcr.2020.08.013>

*Total number of authors:*  
10

*Creative Commons License:*  
CC BY-NC-ND

### General rights

Unless other specific re-use rights are stated the following general rights apply:  
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

### Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117  
221 00 Lund  
+46 46-222 00 00

## Article

# Direct Reprogramming of Human Fetal- and Stem Cell-Derived Glial Progenitor Cells into Midbrain Dopaminergic Neurons

Sara Nolbrant,<sup>1</sup> Jessica Giacomoni,<sup>1</sup> Deirdre B. Hoban,<sup>1</sup> Andreas Bruzelius,<sup>2</sup> Marcella Birtele,<sup>1</sup> Devin Chandler-Militello,<sup>3</sup> Maria Pereira,<sup>1</sup> Daniella Rylander Ottosson,<sup>2</sup> Steven A. Goldman,<sup>3,4,5</sup> and Malin Parmar<sup>1,\*</sup>

<sup>1</sup>Developmental and Regenerative Neurobiology, Wallenberg Neuroscience Center, and Lund Stem Cell Centre, Department of Experimental Medical Science, Lund University, Lund, Sweden

<sup>2</sup>Regenerative Neurophysiology, Wallenberg Neuroscience Center, Lund Stem Cell Center, Department of Experimental Medical Science, Lund University, Lund, Sweden

<sup>3</sup>Center for Translational Neuromedicine and Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA

<sup>4</sup>Center for Neuroscience, University of Copenhagen Faculty of Health and Medical Sciences, Copenhagen, Denmark

<sup>5</sup>Neuroscience Center, Rigshospitalet, Copenhagen, Denmark

\*Correspondence: [malin.parmar@med.lu.se](mailto:malin.parmar@med.lu.se)

<https://doi.org/10.1016/j.stemcr.2020.08.013>

## SUMMARY

Human glial progenitor cells (hGPCs) are promising cellular substrates to explore for the *in situ* production of new neurons for brain repair. Proof of concept for direct neuronal reprogramming of glial progenitors has been obtained in mouse models *in vivo*, but conversion using human cells has not yet been demonstrated. Such studies have been difficult to perform since hGPCs are born late during human fetal development, with limited accessibility for *in vitro* culture. In this study, we show proof of concept of hGPC conversion using fetal cells and also establish a renewable and reproducible stem cell-based hGPC system for direct neural conversion *in vitro*. Using this system, we have identified optimal combinations of fate determinants for the efficient dopaminergic (DA) conversion of hGPCs, thereby yielding a therapeutically relevant cell type that selectively degenerates in Parkinson's disease. The induced DA neurons show a progressive, subtype-specific phenotypic maturation and acquire functional electrophysiological properties indicative of DA phenotype.

## INTRODUCTION

Somatic cells can be directly converted into induced neurons (iNs) without a stem cell intermediate using defined sets of transcription factors, microRNAs, and/or through chemical manipulations. Since the original report (Vierbuchen et al., 2010), a number of studies have shown conversion of human fibroblasts into subtype-specific neurons, including dopaminergic (DA) neurons, striatal medium spiny neurons, peripheral sensory neurons, noradrenergic neurons, cholinergic neurons, and spinal motor neurons using different combinations of lineage specific transcription factors (Blanchard et al., 2015; Caiazzo et al., 2011; Li et al., 2019; Liu et al., 2013; Pfisterer et al., 2011; Son et al., 2011; Victor et al., 2014). Direct neural conversion opens up new possibilities to generate patient- and disease-specific neurons from somatic cells and is predicted to have a great impact on disease modeling, diagnostics, and other biomedical applications (Drouin-Ouellet et al., 2017b; Mertens et al., 2018).

Direct conversion could potentially also be used to generate neurons for transplantation-based cell replacement therapies. So far, a number of somatic cell types, including fibroblasts, hepatocytes, pericytes, and glia, have been successfully converted to neurons (Masserdotti et al., 2016). Since the direct conversion strategy does not rely on a proliferative intermediate, some of the safety con-

cerns associated with the use of human pluripotent stem cells (hPSCs) are minimized, and both autologous and allogeneic strategies could be used (Fang et al., 2018; Grealish et al., 2016). As an extension of direct conversion in cell-based therapies, delivery of the conversion factors directly to the brain with the aim of converting endogenous glia is being developed as an alternative approach for the generation of therapeutic neurons *in situ* (Vignoles et al., 2019). In support of this concept, resident astrocytes and glial progenitor cells (GPCs, also called oligodendrocyte progenitor cells or NG2 cells) have been successfully converted into neurons in the mouse brain (Guo et al., 2014; Mattugini et al., 2019; Niu et al., 2015; Pereira et al., 2017; Qian et al., 2020; Rivetti di Val Cervo et al., 2017; Torper et al., 2015). For translational applications, it is important to document the conversion of human glia into subtype-specific and functional neurons. Initially, this can be done using *in vitro* cultures of human brain-derived cells and so far, human astrocytes and pericytes have been shown to generate functional and subtype-specific neurons after conversion *in vitro* (Guo et al., 2014; Karow et al., 2012). The possibility to convert human GPCs (hGPCs) *in vitro* has not yet been explored even though these cells may be more suitable than astrocytes for *in situ* conversion, because GPCs remain proliferative in the adult brain (Hughes et al., 2013; Simon et al., 2011). Proof of concept for GPC conversion has been obtained in mouse models



*in vivo* (Guo et al., 2014; Heinrich et al., 2014; Pereira et al., 2017; Torper et al., 2015). However, studies of human GPC conversion are challenging because GPCs are not born until late in the second trimester, which limits their accessibility because it is difficult to source human embryos for cell isolation and subsequent *in vitro* cultures (Jakovcevski and Zecevic, 2005; Sim et al., 2011).

In this study, we show that hGPCs isolated from the human fetal brain can be efficiently converted into neurons *in vitro*, which provides important proof of concept for the approach. However, access to human fetal cells is limited, and we therefore sought to establish a human pluripotent stem cell (hPSC)-based experimental model system for hGPC reprogramming studies. To achieve this, we differentiated human embryonic stem cells (hESCs) into hGPCs, based on the protocol by Wang et al. (2013), and show that these hESC-derived hGPCs convert into iNs in a similar manner to the hGPCs isolated from the human fetal brain. We used stem cell-derived hGPCs to assess the effect of fate-determining genes with a focus on DA neurons, the principal neuronal subtype lost in Parkinson's disease (PD), and thus a therapeutically important cell type. We found that hGPCs can be directly converted into TH<sup>+</sup> neurons using several different combinations of transcription factors and microRNAs. The resulting TH<sup>+</sup> neurons have a gene and protein expression profile similar to mature midbrain DA neurons and adopt electrophysiological properties typical of functional DA neurons.

Thus, this study provides evidence that hGPCs isolated from both human fetal brain and differentiated from hESCs can be successfully reprogrammed into functional iNs, including induced DA neurons (iDANs).

## RESULTS

### Human Fetal Glial Progenitors Efficiently Convert to Functional iDANs *In Vitro*

To establish the potential of hGPCs to convert into neurons *in vitro*, we used hGPCs isolated from the fetal brain (Figures 1A, 1B and S1A–S1AC) (Benraiss et al., 2016) and transduced them with doxycycline (dox)-inducible vectors carrying the conversion factors *Ascl1*, *Lmx1a*, and *Nr4a2* (*Nurr1*), (together referred to as ALN), a combination of factors that has previously been used to successfully reprogram human fetal fibroblasts into iDANs (Caiazzo et al., 2011; Torper et al., 2013) together with short hairpin (sh) RNA against the RE1-silencing transcription factor (REST) complex. Already at 1 week after transgene activation, glial markers were downregulated, and some TH<sup>+</sup>/MAP2<sup>+</sup> cells could be detected in the cultures (Figure S1D). After an additional 2 weeks, the reprogrammed cells showed a more pronounced neuronal morphology and expressed


many DA-related genes, including *TH*, *SLC6A3* (*DAT*), *FOXA2*, *LMX1A*, and *PITX3* (Figures 1C, 1E, and S1E). Control cultures of untransduced cells that were kept in parallel in either glial medium or neuronal conversion medium (containing small molecules and growth factors) continued to express GFAP and PDGFR $\alpha$  (Figures S1F and S1G) and did not give rise to any TH<sup>+</sup> neurons (Figures 1D and 1E).

Whole-cell patch-clamp recordings were performed after 80–120 days *in vitro* and confirmed functional maturation of the hGPC-derived iNs. At this point, the reprogrammed neurons (n = 37) exhibited the ability to fire evoked action potentials (APs) in the form of single and multiple APs (multiple APs, 14%; single APs, 22%; n = 37) (Figure 1G and Table S1). The cells also displayed fast-inactivated inward and outward currents characteristic of sodium and delayed-rectifier potassium currents (Figure 1H), as well as spontaneous postsynaptic activity (Figure 1I), suggestive of synaptic engagement. Moreover, a proportion of the converted neurons developed spontaneous firing at resting membrane potential (7/25 converted neurons; Figure 1J), a characteristic typical of DA neurons.

Taken together, this establishes the ability of fetal hGPCs to be reprogrammed into functional iNs, with a gene and protein expression profile and functionality indicative of a DA identity using ALN + shREST. However, hGPCs arise late in the gestational time period, following the neuron-to-glial cell switch, and are therefore difficult to obtain from the limited amounts of fetal brain tissue available at this late gestational time point (Rowitch and Kriegstein, 2010; Sim et al., 2011). To enable larger experimental studies of hGPC conversion, we set out to develop a more accessible experimental *in vitro* system.

### Establishing a Pluripotent Stem Cell-Based Model System for hGPC Reprogramming

To establish an *in vitro* model system for direct neuronal conversion using cells that are as close as possible to the bona fide hGPCs in the brain, we used a previously published protocol for generating hGPCs from hPSCs (Wang et al., 2013). The protocol was adapted to a defined and xeno-free hESC culture system for maintenance of hPSCs on recombinant human laminin, in iPS Brew medium. We also established a cryopreservation step in order to improve the logistics and reproducibility of the protocol (Figure 2A). During the glial differentiation of the hESCs, the proportion of cells positive for CD140 (PDGFR $\alpha$ ), which identifies myelinogenic and migration-competent human oligodendrocyte progenitor cells (Sim et al., 2011), increases with time in culture (Figure S2A). Cells generated from two different hESC lines (RC17 and HS1001) were expanded and cryopreserved from day 160 up to day 250 (Figures 2A and 2B). At this point, the



### Figure 1. Fetal hGPCs Can Be Converted to Induced DA Neurons *In Vitro*

(A and B) Fetal hGPCs visualized by bright field imaging (A) or stained for GFAP and PDGFR $\alpha$  (B).

(C) Reprogrammed TH<sup>+</sup>/TAU<sup>+</sup> neurons 3 weeks after transgene activation.

(D and E) hGPCs kept in parallel for 3 weeks in neuronal conversion medium (D) or glial medium (E) do not give rise to any TH<sup>+</sup>/TAU<sup>+</sup> neurons.

(F) qPCR analysis of reprogrammed cells 3 weeks after transgene activation shows an upregulation of pan-neuronal and DA genes.

(G) Representative trace of voltage responses from the whole-cell patch-clamp technique showing multiple induced APs.

(H) Representative trace of inward sodium- and outward potassium-rectifying currents triggered by stepwise depolarization of the cell.


(I and J) The reprogrammed fetal hGPCs show spontaneous postsynaptic currents (I) and spontaneous firing at their resting membrane potential (J).

In [Figure 1F](#), data are presented as means  $\pm$  SEM, and all data points have been visualized in the graphs. Each data point represents a replicate from an independent experiment ( $n = 5$  for ALN + shREST;  $n = 2$  for CNTRL-NDIFF;  $n = 3$  for CNTRL-GM). Scale bars: (A, B, D, and E) 100  $\mu$ m; (C) 50  $\mu$ m. See also [Figure S1](#).

majority of the cells were positive for CD140, and we confirmed that this phenotype was maintained following cryopreservation ([Figures 2C, 2D, and S2A–S2E](#)). The glial marker CD44 labels astrocyte biased progenitors, or when co-expressed with CD140, bipotential glial progenitors. In contrast to CD140, the proportion of CD44<sup>+</sup> cells did not increase with time in culture ([Figure S2A](#)), and the cryopreservation procedure did not significantly affect the rela-

tive proportion of CD44<sup>+</sup> cells in the culture ( $p = 0.952$ ; paired, two-tailed  $t$  test). Under these culture conditions, very few if any cells expressed neuronal TAU (HT7) or MAP2a/MAP2b ([Figures S2F and S2G](#)), whereas MAP2c, an isoform of MAP2 that is expressed in developing progenitors, both neuronal and oligodendroglial ([Garner et al., 1988; Vouyiouklis and Brophy, 1995](#)), was abundantly expressed ([Figure S2F](#)). Rare TH<sup>+</sup> cells could also be found in






**Figure 2. Establishing a Renewable and Reproducible Source of hGPCs from hESCs for *In Vitro* Modeling of Direct Neuronal Conversion**

(A) Schematic overview of the protocol for generating hESC-derived hGPCs, with an indication of the time frame used for cryopreservation. (B) Bright-field images of the hESC-derived hGPCs cultures at different stages and before and after cryopreservation. (C) GFAP/PDGFR $\alpha$  immunostaining of the hESC-derived hGPC cultures at different stages and before and 15 days after cryopreservation. Insets show close-up morphology of cells in the boxed areas. (D) Percentage of CD140<sup>+</sup> cells within the cultures before and after cryopreservation as determined by flow cytometry. (E and F) TH<sup>+</sup>/TAU<sup>+</sup> cells (E) and NEUN<sup>+</sup> cells (F) 3 weeks after activation of the transgenes ALN + shREST in hESC-derived hGPCs. The proportions of CD140<sup>+</sup> cells in Figure 2D were compared using a paired two-tailed t test; \*p < 0.05 (p = 0.0327). Scale bars: 100  $\mu$ m. See also Figures S2 and S3.

both fetal- and hESC-derived hGPC cultures, but co-labeling with glial and neuronal markers confirmed that these cells were of a glial identity, since TH was only found co-labeled with glial markers and not with neuronal markers (Figures S1C, S2G, and S2H).

We next assessed whether cryopreserved hESC-derived hGPCs could be converted into iDANs using the same protocol and the same combination of reprogramming factors (ALN + shREST) as was used for the fetal hGPCs. In accord with our observations in converting fetal progenitors, some TH<sup>+</sup> neurons could be detected 1 week after conversion (Figure S3A). Three weeks after activation of ALN + shREST, the glial markers were efficiently downregulated, and the

cultures contained few if any GFAP<sup>+</sup> or PDGFR $\alpha$ <sup>+</sup> cells (Figure S3B). Control cells that were not transduced but cultured in neuronal conversion medium (Figures S3C and S3D), as well as control glial cultures that were analyzed in parallel (Figure S3E), maintained their glial identity (Figures S3D and S3E), and no TH<sup>+</sup> neurons were detected (Figure S3C). At this time point, reprogrammed cells with a clear neuronal morphology that were positive for TH/TAU and NEUN were observed only after reprogramming with ALN + shREST (Figures 2E, 2F, and 5G). Together, these data establish that both fetal hGPCs and hESC-derived hGPCs can be converted to TH<sup>+</sup> iNs, using the same factors and with comparable timing and



### Figure 3. Direct Conversion of Purified CD140-expressing Progenitors

(A) Schematic overview of the strategy for neuronal conversion of CD140-sorted and unsorted cells side by side. Astrocyte biased progenitors are depicted in green, oligodendrocyte biased progenitors are depicted in pink, bipotent glial progenitors are depicted in purple, and cells of an unknown identity are depicted in blue.

(B and C) CD140-sorted hGPCs are positive for OLIG2/SOX10 (B) and PDGFR $\alpha$  (C). A subset of the hGPCs are positive for GFAP (B and C), representing a bipotent progenitor state.

(D and E) TH<sup>+</sup>/TAU<sup>+</sup> cells 3 weeks after reprogramming, starting from either unsorted (neuronal proportion, 53.7%; TH<sup>+</sup> neuronal proportion, 1.7%; D) or CD140-sorted (neuronal proportion, 57.0%; TH<sup>+</sup> neuronal proportion, 1.3%; E) hESC-derived hGPCs.

Scale bars: (C) 100  $\mu$ m; (B, D, and E) 50  $\mu$ m. See also Figure S4.

efficiencies (Figures S1E and 5G). No significant differences were noted between fetal- and hESC-derived cells in the relative proportions of either neurons ( $p = 0.102$ ) or TH<sup>+</sup> neurons ( $p = 0.139$ ; both determined using unpaired, two-tailed t tests). These data support the applicability of our stem cell-based model system for neuronal conversion studies.

### Purified Populations of hESC-Derived hGPCs Can Be Converted to TH<sup>+</sup> INs


We initiated conversion from hESC-derived hGPCs at different time points, ranging from day 160 to day 270 in culture (corresponding to passage 2–6 of the hGPCs; see Table S2) and established that the time in culture did not affect the efficiency of the hGPCs to convert into iNs, based on the comparable induction of TH and SYNAPSIN 1 (SYN1) as assessed 3 weeks after initiation of reprogramming (Figure S3F). The differentiation protocol used here results in primarily oligodendrocyte biased progenitors (CD140<sup>+</sup>/CD44<sup>-</sup>) but also produces a minority of bipotential (CD140<sup>+</sup>/CD44<sup>+</sup>) and astrocyte biased (CD140<sup>-</sup>/CD44<sup>+</sup>) progenitors. By analyzing neuronal conversions from different glial differentiation runs containing varying

ratios of these three subtypes of glial progenitors (Table S2), we found that the induction of SYN1 in the reprogrammed cells correlated positively with a high CD140<sup>+</sup> starting population, and negatively with a high astrocyte progenitor population, while TH expression did not vary in correlation with the composition of cells at the start of neuronal conversion (Figure S3G).

To assess experimentally if a purified population of CD140<sup>+</sup> hGPCs can be converted into TH<sup>+</sup> iNs, we next used fluorescence-activated cell sorting to extract the CD140<sup>+</sup> fraction from the hESC-derived hGPCs cultures (Figures 3A–3C and S4). Importantly, by converting unsorted cells (Figure 3D) and CD140-sorted cells (Figure 3E) from the same batch of hESC-derived hGPCs side by side, we confirmed that using our differentiation strategy, CD140<sup>+</sup> hGPCs are indeed amenable to DA conversion *in vitro*.

### Timed Delivery of Foxa2 Augments DA Reprogramming of Fetal- and Stem Cell-Derived hGPCs

Previous efforts from our lab and others have identified Otx2, Foxa2, Nurr1, NeuroD1, Ascl1, Lmx1a, and mir218



**Figure 4. Direct Conversion of hESC-Derived hGPCs Using Different Combinations of DA Fate Determinants**

(A) Schematic overview of the neuronal conversion protocol indicating the different time points of analysis and references to the figures related to each time point.

(legend continued on next page)





as factors that can improve the DA reprogramming of human fibroblasts and human astrocytes when expressed in specific combinations (Pereira et al., 2014; Rivetti di Val Cervo et al., 2017; Torper et al., 2013). Here, we tested the effect of these additional DA fate determinants when converting hGPCs to DA neurons (Figure 4A). Gene expression analysis 3 weeks after initiation of reprogramming showed that the addition of *Otx2* to the original reprogramming cocktail did not add any beneficial effects in terms of reprogramming efficiency and DA phenotype (Figures S5A–S5C). The *NeuroD1*, *Ascl1*, *Lmx1a*, and *mir218* (NeAL218) factor combination used in Rivetti di Val Cervo et al. (2017) resulted in a comparable number of TH<sup>+</sup> iDANs and a similar gene expression profile as ALN + shREST reprogrammed cells, when assessed 3 weeks after transgene activation (Figures S5D and S5E). In contrast, when *Foxa2* was added to the initial cocktail (Figures 4B and 4C), the gene expression analysis showed a higher endogenous expression of the midbrain DA genes *LMX1B* ( $p = 0.0098$ ), *EN1* ( $p = 0.0001$ ), and *OTX2* ( $p = 0.0075$ ) (Figure 4E). The addition of *Foxa2* also resulted in increased expression of the DA synthesis-related enzyme *DDC* ( $p < 0.0001$ ) (Figure 4E), which was confirmed at the protein level using immunocytochemistry (Figures 4F, 4G, and S5F). At the same time, the proportion of TH<sup>+</sup> neurons in the 3-week culture did not differ significantly between the ALN + shREST and ALN + *Foxa2* + shREST transduced cells ( $p = 0.224$  as determined using an unpaired, two-tailed *t* test and see Figure 5G). We also tested the NeAL218 and ALN + *Foxa2* + shREST factor combinations in the fetal hGPCs and confirmed that while both these combinations successfully generate iNs with a DA phenotype (Figures S5G and S5H), the addition of *Foxa2* again resulted in a higher expression of *LMX1B* and *DDC* (Figure S5I).

Although hESC-derived hGPCs could be reprogrammed into TAU<sup>+</sup> iNs at 3 weeks after transgene activation with an efficiency of 35%–40%, the relative proportion of TH<sup>+</sup> iDANs remained low at this point (Figures 5A, 5B, and 5G). Gene expression analysis at this time point suggested that other subtypes of neurons, such as glutamatergic and

GABAergic neurons, could also be present in the cultures (Figure S6A). To investigate if the proportion of TH<sup>+</sup> neurons increases with time, we maintained the ALN + shREST and ALN + *Foxa2* + shREST reprogrammed cells in long-term culture, with either maintained transgene expression (i.e., continued dox administration to the medium) or with transgene de-activation via dox withdrawal after 3 weeks (Figure 4A). Quantification at day 50 and day 100 (24 and 74 days after dox withdrawal, respectively) showed that the proportion of TH<sup>+</sup> iDANs in both culture conditions was significantly increased over time, reaching as high as 50%, while the neuronal content did not change significantly from the 3-week time point (Figures 5C–5G). The observations that the total number of cells did not change (Figure S6F) and the neuronal proportions were comparable between time points, while the relative proportion of TH<sup>+</sup> neurons increased, suggested that the converted cells undergo progressive DA maturation; this was later confirmed with electrophysiology (see Figure 6). Interestingly, when ALN + shREST was used for conversion, a high number of TH<sup>+</sup> iDANs was generated both with and without dox withdrawal (Figures 5E and S6B), but when *Foxa2* was added to the reprogramming mix, a high number of TH<sup>+</sup> iDANs was only observed when dox was withdrawn from the medium (Figures 5F and S6C). This indicates that while the addition of *Foxa2* to the conversion factor cocktail increased DA-specific conversion initially, maintenance of the exogenous *Foxa2* expression had a negative effect of the subtype identity and maturation of the iDANs. Indeed, the unphysiologically high and/or prolonged expression of *Foxa2* seemed to directly interfere with the expression of TH, since none of the cells that were strongly positive for FOXA2 co-labeled with TH, and the TH<sup>+</sup> neurons only showed weak nuclear labeling of FOXA2 by immunocytochemistry (Figure S6D). Immunocytochemistry confirmed the expression of the mature neuronal- and DA neuron markers SYN1, VMAT2, and ALDH1A1 in long-term cultures of ALN + shREST reprogrammed cells (Figures 5H–5J), and at this late time point, DDC<sup>+</sup> neurons were present in equal quantities in ALN +

(B and C) TH<sup>+</sup>/TAU<sup>+</sup> neurons generated with either ALN + shREST (B) or ALN + *Foxa2* + shREST (C) 3 weeks after transgene activation starting from hESC-derived hGPCs.


(D) No TH<sup>+</sup>/TAU<sup>+</sup> neurons are generated when the hESC-derived hGPCs are kept for 3 weeks in parallel in glial medium.

(E) qPCR analysis of gene expression of iDANs 3 weeks after transgene activation comparing cells reprogrammed with either ALN + shREST or ALN + *Foxa2* + shREST.

(F and G) Immunocytochemical analysis of DDC and FOXA2 in cells reprogrammed using either ALN + shREST (F) or ALN + *Foxa2* + shREST (G).

Data are presented as means  $\pm$  SEM, and all data points have been visualized in the graphs. Each data point represents a replicate from an independent experiment ( $n = 9$ – $12$  for ALN + shREST;  $n = 6$ – $7$  for ALN + *Foxa2* + shREST;  $n = 4$ – $5$  for CNTRL-NDIFF;  $n = 6$ – $8$  for CNTRL-GM). The gene expression levels for the conditions ALN + shREST and ALN + *Foxa2* + shREST were compared using a Mann-Whitney test; \*\* $p < 0.01$  ( $p = 0.0098$  for *LMX1B*,  $p = 0.0075$  for *OTX2*); \*\*\* $p < 0.001$  ( $p = 0.0001$  for *EN1*,  $p < 0.0001$  for *DDC*). Scale bars: 50  $\mu$ m. See also Figure S5.





(legend continued on next page)



shREST and ALN + Foxa2 + shREST reprogrammed cultures (Figures 5K, 5L, and S6G).

### The Reprogrammed iDANs Become Functionally Mature

To better characterize the maturation and functional properties of iDANs at later stages of reprogramming, we focused on ALN + shREST and ALN + Foxa2 + shREST with dox withdrawal from the medium after the first 3 weeks of conversion. Comparing the gene expression profile of the reprogrammed iDANs at 3 weeks with the expression profile at later time points (day 50 and day 100) showed that while the endogenous expression of the DA progenitor markers *LMX1A*, *FOXA2*, and *LMX1B* decreased over time, the expression of the post-mitotic DA markers *TH* and *NURR1* increased (Figure S6E).

To assess the electrophysiological properties of iDANs that had been reprogrammed from hESC-derived hGPCs, whole-cell patch-clamp recordings were performed at day 60 and day 100 of reprogramming. At these time points, no detectable differences in intrinsic membrane properties were observed between the groups (see Table S3). After 60 days (34 days after dox withdrawal), cells reprogrammed with ALN + shREST showed induced APs in higher proportion (9/24 cells firing), compared with ALN + Foxa2 + shREST (1/12 cells firing; Figure 6A). At day 100, the iDANs had matured further, with APs in 21/45 cells for ALN + shREST and 9/45 cells for ALN + Foxa2 + shREST. There was a trend of a greater number of cells displaying multiple APs in ALN + shREST condition compared ALN + Foxa2 + shREST condition (Figures 6A and 6B). The induced APs could be selectively blocked by tetrodotoxin (TTX, 1  $\mu$ M) (Figure S6H). Both ALN + shREST and ALN + Foxa2 + shREST iDANs displayed fast-inactivated inward and outward currents characteristic of sodium and delayed-rectifier potassium currents (Figure 6C and Table S3) as well as spontaneous postsynaptic activity indicative of synaptic integration (Figures 6D and S6I, d100: n = 13/43 for ALN + shREST and 10/41 for ALN + Foxa2 + shREST). iDANs from both conditions also showed the presence of spontaneous firing at resting membrane potential (Figure 6E) and repetitive APs at small current injections (Figure 6F), indicative of a DA phenotype. The proportion of cells exhibiting spontaneous firing was 11% for ALN + shREST and 8% ALN + Foxa2 + shREST at day 60 with a higher proportion at day

100 for the ALN + shREST group (37%). Moreover, the iDANs also showed repetitive AP at small current injections already at day 60 (11% for ALN + shREST and 10% for ALN + Foxa2 + shREST, Figure 6F), a feature that was further increased in ALN + shREST condition at day 100 (ALN + shREST 37%, ALN + Foxa2 + shREST 10%).

Taken together, these results show that hESC-derived hGPCs convert into functional neurons with DA properties that achieve mature profiles after long-term culture.

## DISCUSSION


The potential of cell replacement therapy as a means of treating PD has been established through clinical trials using human fetal ventral midbrain tissue (Barker et al., 2015), and efforts are currently underway with the aim of assessing hPSCs as a source of transplantable DA progenitors (Barker et al., 2017; Doi et al., 2020; Schweitzer et al., 2020). *In vivo* direct reprogramming of resident glia into DA neurons is similarly based on DA neuronal replacement but circumvents cell transplantation, as the new neurons are generated by reprogramming resident cells *in situ* (Grealish et al., 2016; Vignoles et al., 2019).

Several studies have shown that it is possible to obtain subtype-specific and functional neurons via transcription factor-mediated reprogramming of mouse GPCs *in vivo* (Guo et al., 2014; Heinrich et al., 2014; Pereira et al., 2017; Torper et al., 2015) or via inhibition of PTB (Qian et al., 2020), but analogous studies using human cells have been lacking. In this study, we therefore established an *in vitro* model of direct neural conversion from hESC-derived hGPCs. This model has a distinct advantage over existing models that use fetal tissue-derived glia, since generation from stem cells of highly expandable hGPCs provides us with the opportunity to reproducibly assess the biology of neuronal reprogramming from human cells, while doing so at scale using a preferentially permissive but otherwise scarce cell type.

Once established, this hPSC-based experimental model system for hGPC reprogramming studies allowed us to conduct detailed *in vitro* studies of the timeline of reprogramming, the effect of different reprogramming factors, and the phenotypic profile and electrophysiological properties of the reprogrammed iDANs. Using several combinations of transcription factors, including ALN, ALN + Foxa2,

---

Data are presented as means  $\pm$  SEM and all data points have been visualized in the graphs. Each data point represents a replicate from an independent experiment (n = 7 for ALN + shREST at the 3-week time point; n = 5 for ALN + Foxa2 + shREST at the 3-week time point; n = 2 for both conditions at the D50 time point and n = 3 for both conditions at the D100 time point). In (G), the proportion of TAU<sup>+</sup> and TAU<sup>+</sup>/TH<sup>+</sup> cells at the 3-week time point was compared with the late time points day 50 and day 100 combined using an unpaired, two-tailed t test. \*\*\*p < 0.001 (p < 0.0001 for TH<sup>+</sup> cells in ALN + shREST, p < 0.0001 for TH<sup>+</sup> cells in ALN + Foxa2 + shREST); n.s. (p = 0.5307 for TAU<sup>+</sup> cells in ALN + shREST, p = 0.6637 for TAU<sup>+</sup> cells in ALN + Foxa2 + shREST). Scale bars: 50  $\mu$ m. See also Figure S6.



**Figure 6. hESC-Derived hGPCs Reprogrammed iDANs Become Functionally Mature**

(A) Graph showing the number of cells exhibiting multiple, single, or no AP responses evoked by current steps at 60 and 100 days after reprogramming start with ALN + shREST and ALN + Foxa2 + shREST.

(B) Representative trace of voltage responses from the whole-cell patch-clamp technique showing multiple induced APs in cells reprogrammed with ALN + shREST (left, purple) ALN + Foxa2 + shREST (right, green).

(C) Inward sodium current peak (left) and outward potassium current (right) plotted against voltage steps of cells reprogrammed with ALN + shREST (purple) and ALN + Foxa2 + shREST (green).

(D) Spontaneous postsynaptic currents in an ALN + shREST reprogrammed neuron.

(E) Spontaneous firing at resting membrane potential in an ALN + shREST reprogrammed neuron.

(F) Repetitive induced AP at small current injections in an ALN + shREST reprogrammed neuron.

See also [Figure S6](#).

and NeAL218, which have previously been shown to successfully reprogram human fibroblasts and astrocytes into DA neurons (Caiazzo et al., 2011; Rivetti di Val Cervo et al., 2017; Torper et al., 2013), we confirmed that the same factors could successfully reprogram hGPCs as well. Knockdown of REST, which acts to suppress neuronal identity, has previously been shown to greatly increase the efficiency of neuronal reprogramming, starting from adult human fibroblasts (Drouin-Ouellet et al., 2017a). REST is expressed by both GPCs and differentiating astrocytes, where it restricts the neuronal program, and its knockdown has been shown to result in an induction of neuronal genes (Dewald et al., 2011; Kohyama et al., 2010; Liu et al., 2019). Accordingly, the combined knockdown of REST together with ALN resulted in iNs with a DA neuron profile when reprogramming hGPCs. The addition of Foxa2 to the reprogramming cocktail resulted in a stronger endogenous expression of midbrain DA progenitor genes, such as *OTX2*, *LMX1B*, and *EN1* after 3 weeks of conversion, but sustained expression directly interfered with the acquisition of a TH<sup>+</sup> phenotype.

Long-term assessment of the reprogrammed iDANs established that the cells were stably converted and did not rely on continuous expression of conversion factors. Phenotypic and functional assessment using patch-clamp electrophysiology revealed that the reprogrammed neurons matured over time, resulting in an approximately 15-fold increase of TH<sup>+</sup> iDANs in the culture and an adoption of functional electrophysiological properties in line with a DA neuron identity. However, just as when fibroblasts are converted to DA neurons (Caiazzo et al., 2011; Pfisterer et al., 2011; Torper et al., 2013), not all of the reprogrammed cells adopt a DA neuron identity. In this study, we also detected expression of markers suggesting the presence of other subtypes of neurons, including GABAergic and glutamatergic neurons, and the exact phenotype of these neurons remains to be established. Furthermore, while glial markers are rapidly suppressed in these cells, not all glia convert into neurons. This may be due to a technical limitation, in that the conversion factors are delivered on separate vectors, with the result that not all cells are transduced to co-express all factors, and the





stoichiometry of gene expression may vary across the transduced cell population. Going forward, such incompletely transduced or reprogrammed cells will need to be removed before iDANs can be evaluated for clinical use. The reprogrammed neurons matured functionally after long-term culture. However, even at the late time points, a proportion of the neurons were not functionally mature. This can be due to initial asynchrony in reprogramming, culture conditions that may not be ideal for maturation, or insufficient support of mature cells in 2D cultures, and future studies are needed to develop culture conditions more optimal for long-term maintenance of functionally mature cells.

Together, these observations suggest that our hPSC-based system for hGPC reprogramming is effective at reproducibly producing iDANs, while providing a platform for broader studies aiming at converting hGPCs into other subtypes of neurons as well, because it provides scalable populations of reprogramming-permissive human cells. In the current study, we identified combinations of transcription factors that were able to successfully convert both fetal- and stem cell-derived hGPCs directly into functional iDANs. Thus, this study provides an important proof of principle that hPSC-derived hGPCs comprise especially permissive targets for efforts aimed at converting endogenous cells into context-appropriate neurons, in both the diseased and damaged brain, including DA neuronal replacement in PD.

## EXPERIMENTAL PROCEDURES

### hESC Culture and Generation of Human GPCs from hESCs

Glial differentiation was initiated from two different hESC lines: RC17 (RCe021-A, p26-30) and HS1001 (Kie055-A, p8). The undifferentiated hESCs were maintained on LN521 (0.5  $\mu\text{g}/\text{cm}^2$ ; Biolamina)-coated tissue culture plates in iPS Brew XF medium (StemMACS; Milteny) and passaged weekly with EDTA (0.5 mM).

For differentiation of hESCs into hGPCs, the protocol developed in the Goldman lab (Wang et al., 2013) was employed with some minor modifications. For detailed information, see [Supplemental Experimental Procedures](#).

### Culturing of Human Fetal GPCs

Human fetal brain tissue from aborted fetuses (20 weeks gestational age) was obtained with donor consent and under protocols approved by the University of Rochester-Strong Memorial Hospital Research Subjects Review Board. The isolation of glial progenitors from the fetal brain tissue was performed as previously described (Benraiss et al., 2016). The cells were subsequently grown on suspension plates (Greiner Bio-One) in DMEM/F12/N1 medium supplemented with bFGF (10 ng/mL) and 2% PD-FBS at  $2.0 \times 10^5$  cells/mL and passaged every 10–14 days.

### Viral Vectors and Transduction

Doxycycline-regulated lentiviral vectors expressing mouse cDNA and the Tet-On trans-activator (FuW.rTAS-M2; Addgene), have been described previously (Pereira et al., 2014; Pfisterer et al., 2011; Rivetti di Val Cervo et al., 2017). REST shRNA sequences were either expressed in lentiviral constructs under control of a U6 promoter or expressed in a single doxycycline vector construct containing REST shRNA sequences and Ascl1 cDNA. Third-generation lentiviral vectors were produced as previously described (Zuferey et al., 1997) and titrated by quantitative PCR analysis (Georgievska et al., 2004). All viruses used in this study titrated between  $3 \times 10^8$  and  $8 \times 10^9$ . Both fetal- and hESC-derived hGPCs were quite sensitive to the viral transduction, resulting in relatively high levels of cell loss during the early stage of reprogramming compared with starting from fibroblasts for example. This effect showed some cell-batch dependency, and the later inclusion of additional reprogramming factors to the conversion cocktail resulted in an increased viral load, which in general resulted in slightly higher cell death. Therefore, conversion of fetal- and hESC-derived hGPCs required lower multiplicities of infections (MOI; 0.5–2) compared with studies using fibroblasts (Drouin-Ouellet et al., 2017a).

### Direct Neuronal Conversion of Human GPCs

Fetal hGPCs or hESC-derived hGPCs were seeded in their normal culturing medium on plates that had been serially coated with polyornithine (PO), laminin (Lam), and fibronectin (FN), at a density of 50,000 cells/ $\text{cm}^2$ . For electrophysiological analysis, the cells were seeded onto PO/Lam/FN-coated coverslips that had been pre-treated according to Richner et al. (2015). One day after seeding, the cells were transduced at an MOI of 0.5–1 per vector (fetal hGPCs) or MOI of 1–2 per vector (hESC-derived hGPCs), and the medium was changed the next day to remove the viral vectors. Doxycycline (2  $\mu\text{g}/\text{mL}$ ) was added to the culture medium 5 days after transduction to activate the transgenes, and 2 days later the medium was switched to neural differentiation medium (NDiff227; Takara-Clontech) containing the following small molecules (SMs): CHIR99021 (2  $\mu\text{M}$ ; Axon), SB-431542 (10  $\mu\text{M}$ ; Axon), noggin (0.5  $\mu\text{g}/\text{mL}$ ; R&D Systems), LDN-193189 (0.5  $\mu\text{M}$ ; Axon), and valproic acid sodium salt (VPA 1 mM; Merck Millipore); and the following growth factors (GFs): LM-22A4 (2  $\mu\text{M}$ ; R&D Systems), GDNF (2 ng/mL; R&D Systems), NT3 (10 ng/mL; R&D Systems), and db-cAMP (0.5 mM; Sigma). Two-thirds of the medium was changed every 2–3 days. Two weeks post transduction, the SMs were withdrawn from the neuronal differentiation medium, and the medium was supplemented with only the GFs until the end of the experiment. For long-term assessment of the maturation of the reprogrammed cells, doxycycline was either kept in the medium until the end or withdrawn 3 weeks post transgene activation.

### Immunocytochemistry

The cells were fixed in 4% paraformaldehyde solution for 15 min at room temperature (RT) before staining. The cells were pre-incubated in a blocking solution containing 0.1 M phosphate buffered saline with potassium (KPBS) + 0.1% Triton + 5% serum (of secondary antibody host species) for 1–3 h before the primary antibody solution was added (see [Table S4](#)). The cells were incubated with





the primary antibodies over night at 4°C, and washed with KPBS the following day before adding the secondary antibody solution containing fluorophore-conjugated antibodies (1:200; Jackson ImmunoResearch Laboratories) and DAPI (1:500). The cells were incubated with the secondary antibodies for 2 h at RT and finally washed with KPBS.

### qRT-PCR

RNA was isolated from the cells using the RNeasy Micro kit (QIAGEN). Reverse transcription was performed with a Maxima First Strand cDNA Synthesis Kit for RT-qPCR (Thermo Fisher Scientific), using 0.2–0.5 µg of RNA per sample. The cDNA (1 µL) was pipetted together with LightCycler 480 SYBR Green I Master (5 µL; Roche) and relevant primers (4 µL, see [Table S5](#); Integrated DNA Technologies) using the Bravo pipetting robot instrument (Agilent) and analyzed by qRT-PCR on a LightCycler 480 II instrument (Roche) using a 40× cycle two-step protocol with a 60°C, 1-min annealing/elongation step and a 95°C, 30-s denaturation step. All samples were run in technical triplicates, and the average CT values were used for calculating the relative gene expression using the  $\Delta\Delta CT$  method. All fold changes were calculated as the average fold change based on two different housekeeping genes (b-actin and GAPDH) relative to the starting cells before conversion was initiated.

### High Content Analysis

Cells were imaged at 10× magnification using a Cellomics Array Scan VTI HCS reader (Thermo Fisher Scientific). The total number of cells per well positive for DAPI, TAU, and TH were quantified using HCS Studio 3.0 Scan software (Thermo Fischer), which is an automated process enabling unbiased assessment of fluorescence intensity and distribution. Applying the program “Target Activation,” data from 289 fields were collected from the entire well (corresponding to an average number of 21,049 cells). TAU<sup>+</sup> neurons were defined as cells containing a DAPI<sup>+</sup> nuclei and a Cy2-TAU average fluorescence intensity above background of internal negative control cells. TH<sup>+</sup> neurons were defined as TAU<sup>+</sup> neurons with a Cy3-TH average fluorescence intensity above background of internal negative control cells.

### Statistical Analysis

All data are expressed as means ± standard error of the mean (SEM). For gene expression analysis and cellomics analysis, n represent replicates from independent experiments. A Shapiro-Wilk normality test was used to assess the normality of the distribution, and parametric or nonparametric tests were performed accordingly.

For comparing the proportions of CD140<sup>+</sup> cells before and after cryopreservation in [Figure 2D](#), a paired, two-tailed t test was used. For qPCR data related to [Figure 4E](#), outliers were identified using Grubbs's test and removed from the dataset. Since normality could not be proven, a Mann-Whitney test was used to compare the gene expression levels of ALN + shREST and ALN + Foxa2 + shREST. To compare the number of TAU<sup>+</sup> and TAU<sup>+</sup>/TH<sup>+</sup> at early and late time point in [Figure 5G](#), the 3-week time point was compared with day 50 and day 100 combined using an unpaired, two-tailed t test. In [Figures S3F](#) and [S3G](#), correlations were assessed

using Pearson's r. In [Figures S5F](#) and [S6H](#), the proportions of DDC<sup>+</sup> cells were compared using unpaired, two-tailed t tests.

Statistical analyses were conducted using GraphPad Prism 8.0.

### SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at <https://doi.org/10.1016/j.stemcr.2020.08.013>.

### AUTHOR CONTRIBUTIONS

S.N. conceived the project, designed and performed the conversion experiments with hESC-derived and fetal-derived hGPCs, interpreted data, and analyzed results; J.G. performed experiments, interpreted data, and analyzed results; D.B.H. designed and performed conversion experiments with fetal hGPCs and analyzed the results; A.B. and M.B. performed, analyzed, and interpreted patch-clamp experiments and wrote part of the paper; M. Pereira designed and performed conversion experiments with human fetal GPCs; D.R.O. designed, performed, analyzed, and interpreted patch-clamp experiments; S.A.G. designed experiments and interpreted results; M. Parmar conceived the project, designed experiments, and interpreted results. S.N. and M. Parmar wrote the paper with input from all authors.

### ACKNOWLEDGMENTS

We thank Anna Hammarberg, Sol Da Rocha Baez, Jenny Johansson, Ulla Jarl, and Marie Persson Vejgård for excellent technical assistance; members of Steve Goldman's group at the University of Rochester for help with transferring the protocol for hESC-based generation of hGPCs to Lund; and Ernest Arenas for kindly providing virus plasmids. The research leading to these results has received funding from the New York Stem Cell Foundation (M. Parmar), the European Research Council (ERC grant agreement no. 771427, M. Parmar), the Swedish Research Council (grant agreements 2016-00873, M. Parmar; 2017-01234, D.R.O.), Swedish Parkinson Foundation (Parkinsonfonden, M. Parmar), Jeansson Foundation (Jeansson stiftelser, D.R.O.), Swedish Brain Foundation (Hjärnfonden, M. Parmar), the Strategic Research Area at Lund University Multipark (Multidisciplinary research in Parkinson's disease), Knut och Alice Wallenberg Foundation (2018.0040, M. Parmar), National Institute of Neurological Disorders and Stroke (NINDS, S.A.G.), National Institute of Mental Health (NIMH, S.A.G.), ADELSON Medical Research Foundation (S.A.G.), Novo Nordisk Foundation (S.A.G.), Lundbeckfonden (S.A.G.), Oscine Corp. and Sana Biotechnology (S.A.G.). M. Parmar is a New York Stem Cell Foundation Robertson Investigator.

Received: February 28, 2020

Revised: August 25, 2020

Accepted: August 26, 2020

Published: September 24, 2020

### REFERENCES

Barker, R.A., Drouin-Ouellet, J., and Parmar, M. (2015). Cell-based therapies for Parkinson disease—past insights and future potential. *Nat. Rev. Neurol.* *11*, 492–503.



- Barker, R.A., Parmar, M., Studer, L., and Takahashi, J. (2017). Human trials of stem cell-derived dopamine neurons for Parkinson's disease: dawn of a new era. *Cell Stem Cell* *21*, 569–573.
- Benraiss, A., Wang, S., Herrlinger, S., Li, X., Chandler-Militello, D., Mauceri, J., Burm, H.B., Toner, M., Osipovitch, M., Jim Xu, Q., et al. (2016). Human glia can both induce and rescue aspects of disease phenotype in Huntington disease. *Nat. Commun.* *7*, 11758.
- Blanchard, J.W., Eade, K.T., Szucs, A., Lo Sardo, V., Tsunemoto, R.K., Williams, D., Sanna, P.P., and Baldwin, K.K. (2015). Selective conversion of fibroblasts into peripheral sensory neurons. *Nat. Neurosci.* *18*, 25–35.
- Caiazzo, M., Dell'Anno, M.T., Dvoretzkova, E., Lazarevic, D., Taverna, S., Leo, D., Sotnikova, T.D., Menegon, A., Roncaglia, P., Colciago, G., et al. (2011). Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. *Nature* *476*, 224–227.
- Dewald, L.E., Rodriguez, J.P., and Levine, J.M. (2011). The RE1 binding protein REST regulates oligodendrocyte differentiation. *J. Neurosci.* *31*, 3470–3483.
- Doi, D., Magotani, H., Kikuchi, T., Ikeda, M., Hiramatsu, S., Yoshida, K., Amano, N., Nomura, M., Umekage, M., Morizane, A., et al. (2020). Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson's disease. *Nat. Commun.* *11*, 3369.
- Drouin-Ouellet, J., Lau, S., Brattas, P.L., Rylander Ottosson, D., Pircs, K., Grassi, D.A., Collins, L.M., Vuono, R., Andersson Sjolund, A., Westergren-Thorsson, G., et al. (2017a). REST suppression mediates neural conversion of adult human fibroblasts via microRNA-dependent and -independent pathways. *EMBO Mol. Med.* *9*, 1117–1131.
- Drouin-Ouellet, J., Pircs, K., Barker, R.A., Jakobsson, J., and Parmar, M. (2017b). Direct neuronal reprogramming for disease modeling studies using patient-derived neurons: what have we learned? *Front Neurosci.* *11*, 530.
- Fang, L., El Wazan, L., Tan, C., Nguyen, T., Hung, S.S.C., Hewitt, A.W., and Wong, R.C.B. (2018). Potentials of cellular reprogramming as a novel strategy for neuroregeneration. *Front. Cell. Neurosci.* *12*, 460.
- Garner, C.C., Brugg, B., and Matus, A. (1988). A 70-kilodalton microtubule-associated protein (MAP2c), related to MAP2. *J. Neurochem.* *50*, 609–615.
- Georgievska, B., Jakobsson, J., Persson, E., Ericson, C., Kirik, D., and Lundberg, C. (2004). Regulated delivery of glial cell line-derived neurotrophic factor into rat striatum, using a tetracycline-dependent lentiviral vector. *Hum. Gene Ther.* *15*, 934–944.
- Grealish, S., Drouin-Ouellet, J., and Parmar, M. (2016). Brain repair and reprogramming: the route to clinical translation. *J. Intern. Med.* *280*, 265–275.
- Guo, Z., Zhang, L., Wu, Z., Chen, Y., Wang, F., and Chen, G. (2014). In vivo direct reprogramming of reactive glial cells into functional neurons after brain injury and in an Alzheimer's disease model. *Cell Stem Cell* *14*, 188–202.
- Heinrich, C., Bergami, M., Gascon, S., Lepier, A., Vigano, F., Dimou, L., Sutor, B., Berninger, B., and Gotz, M. (2014). Sox2-mediated conversion of NG2 glia into induced neurons in the injured adult cerebral cortex. *Stem Cell Reports* *3*, 1000–1014.
- Hughes, E.G., Kang, S.H., Fukaya, M., and Bergles, D.E. (2013). Oligodendrocyte progenitors balance growth with self-repulsion to achieve homeostasis in the adult brain. *Nat. Neurosci.* *16*, 668–676.
- Jakovcevski, I., and Zecevic, N. (2005). Sequence of oligodendrocyte development in the human fetal telencephalon. *Glia* *49*, 480–491.
- Karow, M., Sanchez, R., Schichor, C., Masserdotti, G., Ortega, F., Heinrich, C., Gascon, S., Khan, M.A., Lie, D.C., Dellavalle, A., et al. (2012). Reprogramming of pericyte-derived cells of the adult human brain into induced neuronal cells. *Cell Stem Cell* *11*, 471–476.
- Kohyama, J., Sanosaka, T., Tokunaga, A., Takatsuka, E., Tsujimura, K., Okano, H., and Nakashima, K. (2010). BMP-induced REST regulates the establishment and maintenance of astrocytic identity. *J. Cell Biol* *189*, 159–170.
- Li, S., Shi, Y., Yao, X., Wang, X., Shen, L., Rao, Z., Yuan, J., Liu, Y., Zhou, Z., Zhang, Z., et al. (2019). Conversion of astrocytes and fibroblasts into functional noradrenergic neurons. *Cell Rep.* *28*, 682–697.e7.
- Liu, M.L., Zang, T., Zou, Y., Chang, J.C., Gibson, J.R., Huber, K.M., and Zhang, C.L. (2013). Small molecules enable neurogenin 2 to efficiently convert human fibroblasts into cholinergic neurons. *Nat. Commun.* *4*, 2183.
- Liu, Z., Osipovitch, M., Benraiss, A., Huynh, N.P.T., Foti, R., Bates, J., Chandler-Militello, D., Findling, R.L., Tesar, P.J., Nedergaard, M., et al. (2019). Dysregulated glial differentiation in schizophrenia may be relieved by suppression of SMAD4- and REST-dependent signaling. *Cell Rep.* *27*, 3832–3843.e6.
- Masserdotti, G., Gascon, S., and Gotz, M. (2016). Direct neuronal reprogramming: learning from and for development. *Development* *143*, 2494–2510.
- Mattugini, N., Bocchi, R., Scheuss, V., Russo, G.L., Torper, O., Lao, C.L., and Gotz, M. (2019). Inducing different neuronal subtypes from astrocytes in the injured mouse cerebral cortex. *Neuron* *103*, 1086–1095.e5.
- Mertens, J., Reid, D., Lau, S., Kim, Y., and Gage, F.H. (2018). Aging in a dish: iPSC-derived and directly induced neurons for studying brain aging and age-related neurodegenerative diseases. *Annu. Rev. Genet.* *52*, 271–293.
- Niu, W., Zang, T., Smith, D.K., Vue, T.Y., Zou, Y., Bachoo, R., Johnson, J.E., and Zhang, C.L. (2015). SOX2 reprograms resident astrocytes into neural progenitors in the adult brain. *Stem Cell Reports* *4*, 780–794.
- Pereira, M., Birtele, M., Shrigley, S., Benitez, J.A., Hedlund, E., Parmar, M., and Ottosson, D.R. (2017). Direct reprogramming of resident NG2 glia into neurons with properties of fast-spiking parvalbumin-containing interneurons. *Stem Cell Reports* *9*, 742–751.
- Pereira, M., Pfisterer, U., Rylander, D., Torper, O., Lau, S., Lundblad, M., Grealish, S., and Parmar, M. (2014). Highly efficient generation of induced neurons from human fibroblasts that survive transplantation into the adult rat brain. *Sci. Rep.* *4*, 6330.



- Pfisterer, U., Kirkeby, A., Torper, O., Wood, J., Nelander, J., Dufour, A., Bjorklund, A., Lindvall, O., Jakobsson, J., and Parmar, M. (2011). Direct conversion of human fibroblasts to dopaminergic neurons. *Proc. Natl. Acad. Sci. U S A* *108*, 10343–10348.
- Qian, H., Kang, X., Hu, J., Zhang, D., Liang, Z., Meng, F., Zhang, X., Xue, Y., Maimon, R., Dowdy, S.F., et al. (2020). Reversing a model of Parkinson's disease with in situ converted nigral neurons. *Nature* *582*, 550–556.
- Richner, M., Victor, M.B., Liu, Y., Abernathy, D., and Yoo, A.S. (2015). MicroRNA-based conversion of human fibroblasts into striatal medium spiny neurons. *Nat. Protoc.* *10*, 1543–1555.
- Rivetti di Val Cervo, P., Romanov, R.A., Spigolon, G., Masini, D., Martin-Montanez, E., Toledo, E.M., La Manno, G., Feyder, M., Pifl, C., Ng, Y.H., et al. (2017). Induction of functional dopamine neurons from human astrocytes in vitro and mouse astrocytes in a Parkinson's disease model. *Nat. Biotechnol.* *35*, 444–452.
- Rowitch, D.H., and Kriegstein, A.R. (2010). Developmental genetics of vertebrate glial-cell specification. *Nature* *468*, 214–222.
- Schweitzer, J.S., Song, B., Herrington, T.M., Park, T.Y., Lee, N., Ko, S., Jeon, J., Cha, Y., Kim, K., Li, Q., et al. (2020). Personalized iPSC-derived dopamine progenitor cells for Parkinson's disease. *N. Engl. J. Med.* *382*, 1926–1932.
- Sim, F.J., McClain, C.R., Schanz, S.J., Protack, T.L., Windrem, M.S., and Goldman, S.A. (2011). CD140a identifies a population of highly myelinogenic, migration-competent and efficiently engrafting human oligodendrocyte progenitor cells. *Nat. Biotechnol.* *29*, 934–941.
- Simon, C., Gotz, M., and Dimou, L. (2011). Progenitors in the adult cerebral cortex: cell cycle properties and regulation by physiological stimuli and injury. *Glia* *59*, 869–881.
- Son, E.Y., Ichida, J.K., Wainger, B.J., Toma, J.S., Rafuse, V.F., Woolf, C.J., and Eggan, K. (2011). Conversion of mouse and human fibroblasts into functional spinal motor neurons. *Cell Stem Cell* *9*, 205–218.
- Torper, O., Ottosson, D.R., Pereira, M., Lau, S., Cardoso, T., Grealish, S., and Parmar, M. (2015). In vivo reprogramming of striatal NG2 glia into functional neurons that integrate into local host circuitry. *Cell Rep.* *12*, 474–481.
- Torper, O., Pfisterer, U., Wolf, D.A., Pereira, M., Lau, S., Jakobsson, J., Bjorklund, A., Grealish, S., and Parmar, M. (2013). Generation of induced neurons via direct conversion in vivo. *Proc. Natl. Acad. Sci. U S A* *110*, 7038–7043.
- Victor, M.B., Richner, M., Hermansteyne, T.O., Ransdell, J.L., Sobieski, C., Deng, P.Y., Klyachko, V.A., Nerbonne, J.M., and Yoo, A.S. (2014). Generation of human striatal neurons by microRNA-dependent direct conversion of fibroblasts. *Neuron* *84*, 311–323.
- Vierbuchen, T., Ostermeier, A., Pang, Z.P., Kokubu, Y., Sudhof, T.C., and Wernig, M. (2010). Direct conversion of fibroblasts to functional neurons by defined factors. *Nature* *463*, 1035–1041.
- Vignoles, R., Lentini, C., d'Orange, M., and Heinrich, C. (2019). Direct lineage reprogramming for brain repair: breakthroughs and challenges. *Trends Mol. Med.* *25*, 897–914.
- Vouyiouklis, D.A., and Brophy, P.J. (1995). Microtubule-associated proteins in developing oligodendrocytes: transient expression of a MAP2c isoform in oligodendrocyte precursors. *J. Neurosci. Res.* *42*, 803–817.
- Wang, S., Bates, J., Li, X., Schanz, S., Chandler-Militello, D., Levine, C., Maherali, N., Studer, L., Hochedlinger, K., Windrem, M., et al. (2013). Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination. *Cell Stem Cell* *12*, 252–264.
- Zufferey, R., Nagy, D., Mandel, R.J., Naldini, L., and Trono, D. (1997). Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. *Nat. Biotechnol.* *15*, 871–875.


**Stem Cell Reports, Volume 15**

**Supplemental Information**

**Direct Reprogramming of Human Fetal- and Stem Cell-Derived Glial Progenitor Cells into Midbrain Dopaminergic Neurons**

**Sara Nolbrant, Jessica Giacomoni, Deirdre B. Hoban, Andreas Bruzelius, Marcella Birtele, Devin Chandler-Militello, Maria Pereira, Daniella Rylander Ottosson, Steven A. Goldman, and Malin Parmar**






**Fig S1 Characterization of fetal hGPCs. Related to Figure 1.**

(A-C) Immunocytochemical characterization of glial and neuronal markers in three different passages (P2, P5 and P12) of fetal hGPCs, showing stainings of GFAP/PDGFR $\alpha$  (A), TAU/MAP2(a+b+c) (B) and MAP2(a+b)/TH (C).

(D) After 1 weeks of transgene activation, induced TH<sup>+</sup>/MAP2<sup>+</sup> neurons appear in the culture and the number of GFAP<sup>+</sup> cells decrease.

(E) Quantifications of neuronal proportion ( $56.3 \pm 5.6\%$ ) and TH<sup>+</sup> neuronal proportion ( $1.25 \pm 0.69\%$ ) after three weeks of reprogramming.

(F and G) GFAP<sup>+</sup> and PDGFR $\alpha$ <sup>+</sup> hGPCs kept in glial medium (F) or neuronal conversion medium (G) for 3 weeks in parallel to reprogrammed cells. In Fig S1E, data are presented as mean  $\pm$  SEM and all data points have been visualized in the graphs. Each data point represents a replicate from an independent experiment. Scale bars: 100  $\mu$ m.



**Fig S2 Characterization of hESC-derived hGPCs. Related to Figure 2.**


(A) Flow cytometry analysis of the expression of CD140 and CD44 over time and following cryopreservation of hGPCs at day 190 of differentiation +15 days post thaw.

(B-E) Immunocytochemical characterization of glial markers in hESC-derived hGPCs at different stages and before and after cryopreservation shows cells positive for GFAP, OLIG2 and SOX10 (B), GFAP, OLIG2 (C), PDGFR $\alpha$  and O4 (D), and NFIA, but not NGN2 (E).

(F) Immunocytochemical characterization of MAP2(a+b+c) and TAU in hESC-derived hGPCs at different stages and before and after cryopreservation

(G-H) Cultures of hESC-derived hGPCs contain rare TH<sup>+</sup> cells. These TH<sup>+</sup> cells are of a glial identity since they do not co-label with MAP2 (a+b), TAU or NEUN (G, indicated with a blue arrows), but instead co-label with GFAP and PDGFR $\alpha$  (H, indicated with white arrows). Scale bars: (A–C, F, H) 100  $\mu$ m; (D, G) 50  $\mu$ m.





**Fig S3 Direct neuronal reprogramming of hESC-derived hGPCs. Related to Figure 2.**

(A) After 1 week of transgene activation, induced TH<sup>+</sup>/MAP2<sup>+</sup> neurons appear in the culture.

(B) 3 weeks after transgene activation, GFAP<sup>+</sup> and PDGFR $\alpha$ <sup>+</sup> cells completely disappear from the culture.

(C) hESC-derived hGPCs kept in parallel in neuronal conversion medium for 3 weeks do not give rise to any TH<sup>+</sup>/TAU<sup>+</sup> neurons.


(D and E) GFAP<sup>+</sup> and PDGFR $\alpha$ <sup>+</sup> cells are maintained when the hESC-derived hGPCs are kept in neuronal conversion medium (D) and glial medium (E).

(F) Days in culture prior to the reprogramming does not affect the induction of *TH* or *SYN1* in the reprogrammed cultures.

(G) The variable proportion of the different progenitor types in different starting cell batches affects the induction of *SYN1*, but not of *TH*, in the reprogrammed cells.


In Fig S3F and S3G, each data point represents a replicate from an independent experiment and correlations have been assessed using Pearson's *r*.

Scale bars: (A) 50  $\mu$ m; (B-E) 100  $\mu$ m.



**Fig S4. FACS sorting of CD140<sup>+</sup> cells for neuronal reprogramming. Related to Figure 3.**  
 (A-C) FACS plots showing the gating strategy for sorting CD140<sup>+</sup> single cells and reanalysis plot to assess the stringency of the strategy. Unstained cells are shown in (A), CD140-stained cells are shown in (B) and re-analyzed CD140-stained cells are shown in (C).














**Fig S5 Assessment of factor combinations for direct conversion to a DA fate. Related to Figure 4.**

(A) qPCR analysis of reprogrammed cells 3 weeks after transgene activation comparing cells reprogrammed with ALN+shREST, or with ALN+shREST together with Otx2 and/or Foxa2.  
 (B-D) TH<sup>+</sup>/TAU<sup>+</sup> cells generated with either ALN+Otx2+shREST (B), ALN+Otx2+Foxa2+shREST (C), or NeAL218 (D) 3 weeks after transgene activation starting from hESC-derived hGPCs.  
 (E) qPCR analysis of reprogrammed cells 3 weeks after transgene activation comparing cells reprogrammed with either ALN+shREST or NeAL218 starting from hESC-derived hGPCs.  
 (F) Quantification of the proportion of DDC<sup>+</sup> cells in cultures reprogrammed with either ALN+shREST or ALN+Foxa2+shREST.  
 (G-H) Fetal primary hGPCs can be reprogrammed into TH<sup>+</sup>/TAU<sup>+</sup> cells using ALN+Foxa2+shREST (F) and NeAL218 (G).  
 (I) Addition of Foxa2 to the reprogramming ALN+shREST cocktail results in a higher expression of *LMX1B* and *DDC* in fetal hGPCs.

In Fig S5A, S5E-F and S5I, data are presented as mean ± SEM and all data points have been visualized in the graphs. For the gene expression data in Fig S5A, S5E and S5I, each data point represents a replicate from an independent experiment. (S5A: n=2; S5E n=5 for ALN+shREST; n=3 for NeAL218; n=3 for CNTRL – GM; S5I: n=5 for ALN+shREST; n=3 for ALN+Foxa2+shREST). The data points displayed for qPCR data for ALN+shREST, ALN+Foxa2+shREST and CNTRLs in Fig S5A and S5E are also included of the comparison of ALN+shREST and ALN+Foxa2+shREST in Fig 4E. The data points displayed for qPCR data of *LMX1B* for ALN+shREST in Fig S5I are also included in Fig 1F. In Fig S5F, the proportions of DDC<sup>+</sup> cells were calculated from 446 (ALN+shREST) and 449 (ALNF+shREST) cells in 4 randomly sampled fields from one experiment. The proportions of DDC<sup>+</sup>/DAPI<sup>+</sup> for the conditions ALN+shREST and ALN+FOXA2+shREST were compared using an unpaired, two-tailed, t-test; \*p<0.05 (p=0.0124). Scale bars: (B-D) 100 μm; (G-H) 50 μm.

**A****B****C****D****E****F****G****H****I**

**Fig S6 Phenotypic maturation of iDANs. Related to Figures 5 and 6.**

(A) qPCR analysis of different neuronal markers in ALN+shREST and ALN+Foxa2+shREST reprogrammed cells 3 weeks after transgene activation.

(B-C) Maintained doxycycline administration does not affect the proportion of TH<sup>+</sup> iDANs when cells are reprogrammed with ALN+shREST (B) but results in a lower proportion on TH<sup>+</sup> neurons when the cells are reprogrammed with ALN+Foxa2+shREST (C).

(D) Cells that show a strong labeling of FOXA2 are not TH<sup>+</sup>. White arrow in right panel indicates a TH<sup>+</sup> cell with weak nuclear labeling of FOXA2.

(E) Gene expression analysis at late timepoint relative to the expression of each gene at the early 3-week timepoint.

(F) Quantification of the proportion of DDC<sup>+</sup> cells in cultures reprogrammed with either ALN+shREST or ALN+Foxa2+shREST after 100 days.

(G) Quantifications of the numbers of cells per well in reprogrammed cultures after 3 weeks, 50 days and 100 days.

(H) Representative trace of voltage responses from whole cell patch clamp technique showing induced AP (purple) selectively blocked by tetrodotoxin (TTX, black).

(I) Pie chart showing different number of cells exhibiting spontaneous postsynaptic activity at 60 and 100 days after reprogramming start with ALN+shREST (left) and ALN+Foxa2+shREST (right).

Data are presented as mean  $\pm$  SEM. In Fig S6A, each data point represents a replicate from an independent experiment (n=9-11 for ALN+shREST; n=7 for ALN+Foxa2+shREST; n=3-5 for CNTRL – NDIFF; n=6-8 for CNTRL – GM). The gene expression levels for the conditions ALN+shREST and ALN+Foxa2+shREST were compared using a Mann-Whitney test; \*\*p<0.01 (p=0.0079 for SERT). In Fig S6E gene expression data was collected from 2 independent experimental replicates per time point and the expression is described relative to the early time point. In Fig S6G, the proportions of DDC<sup>+</sup> cells were calculated from 717 (ALN+shREST) and 1,249 (ALN+Foxa2+shREST) cells in 6-7 randomly sampled fields from one experiment. The proportions of DDC<sup>+</sup>/DAPI<sup>+</sup> for the conditions ALN+shREST and ALN+Foxa2+shREST were compared using an unpaired, two-tailed, t-test (p=0.0901). Scale bars: 50  $\mu$ m.

**Table S1: Summary of electrophysiological properties of fetal hGPCs. Related to Figure 1.**

Intrinsic Properties	ALN + shREST
Resting membrane potential (mV)	d80-120 = $-30.41 \pm 1.51$
Cell capacitance (pF)	d80-120 = $17.94 \pm 1.42$

**Table S2: Cell batches used to as starting cells for reprogramming experiments. Related to Figure 2.**

hESC-line	hGPCs Batch ID	Days in culture	Total CD140 <sup>+</sup> cells	Total CD44 <sup>+</sup> cells	CD140 <sup>+</sup> /CD44 <sup>+</sup>	CD140 <sup>+</sup> /CD44 <sup>-</sup>	CD44 <sup>+</sup> /CD140 <sup>-</sup>
RC17	LU7	165	64.9%	14.7%	8.7%	48.9%	3.7%
RC17	LU3	203	65.2%	28.6%	23.7%	41.4%	0.6%
RC17	LU3	212	65.2%	28.6%	23.7%	41.4%	0.6%
RC17	LU13	238	59.9%	50.8%	52.8%	12.5%	7.2%
RC17	LU16	202	32.4%	23.8%	13.7%	19.8%	10.9%
HS1001	LU27	195	66.7%	3.2%	3.8%	61.2%	0.1%
RC17	LU3	239	60.9%	20.1%	18.3%	42.7%	0.2%
RC17	LU6	271	60.5%	10.0%	10.2%	50.6%	0.2%

**Table S3: Summary of electrophysiological properties of hESC derived hGPC. Related to Figure 6.**

Intrinsic Properties	ALN	ALNF	P (between groups)
Resting membrane potential (mV)	d60 = $-28.64 \pm 1.2$ d100 = $-28.14 \pm 1.1$	d60 = $-25.58 \pm 1.5$ d100 = $-32.88 \pm 0.8$	>0.999 0.086
Cell capacitance (pF)	d60 = $14.81 \pm 1.3$ d100 = $14.46 \pm 1.2$	d60 = $10.36 \pm 1.0$ d100 = $14.78 \pm 1.1$	0.471 >0.999
Input resistance (MΩ)	d60 = $3469 \pm 476.0$ d100 = $3347 \pm 207.6$	D60 = $4928 \pm 402.2$ D100 = $3476 \pm 377.6$	0.247 >0.999

There were no significant differences between the groups or times post-conversion (d60 vs d100) in any of the intrinsic properties. mV = millivolt, pF = picofarad, MΩ = Mega Ohm. One-way ANOVA with Bonferroni multiple comparison post hoc test was used for statistical comparison.



**Table S4: Primary antibodies used in this study. Related to Figure 1-5.**

Antigen	Species	Company (cat. no.)	Dilution
ALDH1A1	Rabbit	Abcam (ab24343)	1:200
DDC	Rabbit	Merck Millipore (AB1569)	1:500
FOXA2	Goat	R&D systems (AF2400)	1:500
GFAP	Mouse	Biologend (SMI 21)	1:500
MAP2	Mouse	Sigma Aldrich (M1406)	1:500
MAP2	Rabbit	Millipore (AB5622)	1:500
NEUN	Rabbit	Millipore (ABN78)	1:500
OLIG2	Rabbit	Neuromics (RA25081)	1:500
O4	Mouse	Merck Millipore (MAB345)	1:100
PDGFR $\alpha$	Rabbit	Cell Signaling Technology (5241S)	1:300
SOX10	Goat	R&D systems (AF2864)	1:25
SYNAPSIN 1	Rabbit	Merck Millipore (AB1543)	1:200
TAU (HT7)	Mouse	Thermo Fisher (MN1000)	1:500
TH	Rabbit	Merck Millipore (AB152)	1:1,000
TH	Sheep	Merck Millipore (AB1542)	1:1,000
VIMENTIN	Chicken	Merck Millipore (AB5733)	1:2,000
VMAT2	Rabbit	Sigma Aldrich (AB1598P)	1:200

**Table S5: Primers used for qRT-PCR analysis. Related to Figure 1 and 4.**

Gene	Full gene name	Primer sequence (fwd/rev)
<i>ACTB</i>	Beta-actin	CCTTGCACATGCCGGAG
		GCACAGAGCCTCGCCTT
<i>CHAT</i>	Choline O-acetyltransferase	TCCAACGAGGACGAGCGTTTGC
		CGAGTCCCGGTTGGTGGAGTCT
<i>DDC</i>	DOPA decarboxylase	GGGGACCACAACATGCTGCTCC
		AATGCACTGCCTGCGTAGGCTG
<i>DAT (SLC6A3)</i>	Dopamine transporter	CACTGCAACAACCTCTGGAA
		AAGTACTCGGCAGCAGGTGT
<i>EN1</i>	Engrailed 1	CGTGGCTTACTCCCCATTTA
		TCTCGCTGTCTCTCCCTCTC
<i>FOXA2</i>	Forkhead box A2	CCGTTCTCCATCAACAACCT
		GGGGTAGTGCATCACCTGTT
<i>GAPDH</i>	Glyceraldehyde-3-phosphate dehydrogenase	TTGAGGTCAATGAAGGGGTC
		GAAGGTGAAGGTCCGAGTCA
<i>GFAP</i>	Glial fibrillary acidic protein	TCATCGCTCAGGAGGTCCTT
		CTGTTGCCAGAGATGGAGGTT
<i>LMX1A (UTR)</i>	LIM homeobox transcription factor a	CGCATCGTTTCTTCTCCTCT
		CAGACAGACTTGGGGCTCAC
<i>LMX1B</i>	LIM homeobox transcription factor b	CTTAACCAGCCTCAGCGACT
		TCAGGAGGCGAAGTAGGAAC
<i>NCAM1</i>	Neural cell adhesion molecule 1	GTCAGAGGCCACCGTCAACGTG
		CTCCCCCTCCCGGAACCTCTG
<i>NR4A2 (NURR1, intron-spanning)</i>	Nuclear receptor subfamily 4, group A, member 2	CAGGCGTTTTTCGAGGAAAT
		GAGACGCGGAGAACTCCTAA
<i>OTX2</i>	Orthodenticle homeobox 2	ACAAGTGGCCAATTCCTCC
		GAGGTGGACAAGGGATCTGA
<i>PDGFRA</i>	Platelet derived growth factor receptor alpha	CCTTGGTGGCACCCCTTAC
		TCCGGTACCCACTCTTGATCTT
<i>PITX3</i>	Paired-like homeodomain 3	GGAGGTGTACCCCGGCTACTCG
		GAAGCCAGAGGCCCCACGTTGA
<i>SERT (SLC6A4)</i>	Serotonin transporter	TGGACCCTCCATTCCACGTCCC
		GTCCTGGAGCCCCTTAGACCCGG
<i>SYP</i>	Synaptophysin	ACCTCGGGACTCAACACCTCCG
		GAACCACAGGTTGCCGACCCAG
<i>SYN1</i>	Synapsin 1	CCCGTGGTTGTGAAGATGGGGC
		TGCCACGACACTTGCGATGTCC
<i>TH</i>	Tyrosine hydroxylase	CGGGCTTCTCGGACCAGGTGTA
		CTCCTCGGCGGTGTACTCCACA
<i>VGAT (SLC32A1)</i>	Vesicular inhibitory amino acid transporter	AGATGATGAGAAACAACCCAG
		CACGACAAGCCAAAATCAC
<i>VGLUT1 (SLC17A7)</i>	Vesicular glutamate transporter 1	AATAACAGCACGACCCACCGCG
		AGCCGTGTATGAGGCCGACAGT

## SUPPLEMENTAL EXPERIMENTAL PROCEDURES

### Generation of human GPCs from hESCs

To initiate the differentiation, the hESCs were detached from the plate using accutase and dissociated to single cells and small cell clusters and kept in iPS-Brew XF medium on day 0 in ultra-low adhesion flasks to allow for embryoid body (EB) formation. On day 0 – day 1, the iPS-Brew XF medium was supplemented with 10  $\mu$ M Y-27632 (ROCK inhibitor; Miltenyi) to improve the survival of single cells. On day 5, the medium was switched to neural induction medium (NIM), containing DMEM/F12 basal medium (Thermo Fisher), MEM Non-Essential Amino Acids (NEAA) Solution (Thermo Fisher), N2 supplement (Thermo Fisher), and Antibiotic-Antimycotic (Thermo Fisher), and supplemented with bFGF (20 ng/ml, Sigma-Aldrich) and Heparin (2  $\mu$ g/ml, STEMCELL Technologies). On day 9, the EBs were attached on Poly-Ornithine/Laminin (PO/Lam) coated tissue culture plates and two days later the medium was changed to NIM + RA (0.1  $\mu$ M, Sigma-Aldrich) and on day 16 the medium was changed to NIM/B27 medium + RA + Purmorphamine (1  $\mu$ M, Millipore). Around day 26-29, the cells were detached from the plates and were seeded as clusters in ultra-low attachment plates. At this stage, the cell quality was assessed by ICC of PAX6, SOX1 and OLIG2 and by FC of CD133 and SSEA4. Following the detachment, the free-floating cell clusters were kept in NIM/B27 medium + Purmorphamine + bFGF (10 ng/ml) up until day 37.

On day 37, the medium was changed to glial medium (GM) containing DMEM/F12 basal medium, B27 supplement, N1 supplement (Sigma-Aldrich), MEM NEAA, Antibiotic-Antimycotic, T3 (60 ng/ml, Sigma-Aldrich), db-cAMP (1  $\mu$ M, Sigma-Aldrich), Biotin (100 ng/ml, Sigma-Aldrich), recombinant human PDGF-AA protein (10 ng/ml, R&D Systems), recombinant human IGF-I (10 ng/ml, R&D Systems) and recombinant human NT-3 Protein (10 ng/ml, R&D Systems), and supplemented with Purmorphamine until day 55 when Purmorphamine was withdrawn from the medium. The cells were then kept in GM for the remaining time in culture. Around day 70, the free-floating clusters were manually cut into smaller pieces using disposable sterile scalpels under a dissection microscope and seeded onto PO/Lam coated tissue culture plates. Thereafter, the cells were passaged and expanded every 30 days, when the clusters were mechanically detached from the plates using a cell scraper, cut at the dissection microscope and re-seeded again at lower density. At every passage, the cells were analyzed by FC for CD44 and CD140 and by ICC for various glial markers. Table S1 specifies the number of days in culture and the proportion of CD140<sup>+</sup>/CD44<sup>+</sup> of the hESC-derived cell batches used in this study.

### Cryopreservation of hESC-derived hGPCs

For cryopreservation of the hESC-derived GPCs, the cell clusters were detached from the plate using a cell scraper, centrifuged at 300 x g for 7 min, resuspended in cold glial medium and dissociated using a 1000  $\mu$ l pipette. The cells were cryopreserved at a density 0.5-1x 6-well per cryovial in 500  $\mu$ l GM. The freezing medium was prepared by supplementing ProFreeze<sup>TM</sup>-CDM NAO Freezing Medium (2X, Lonza) with 15 % DMSO and was added dropwise to the cryovial containing the cell suspension at equal proportions (giving a final concentration of DMSO of 7.5 %). The cryovials were then moved into a controlled-rate alcohol-free cell freezing container and kept at -80°C overnight. The following day the cells were moved to a -150°C freezer or a Liquid Nitrogen tank for long-term storage.

### Electrophysiology

Whole cell patch-clamp electrophysiological recordings were performed at day 60 and 100 post-conversion. Cells were cultured on glass coverslips and transferred to a recording chamber with constant flow of Krebs solution gassed with 95 % O<sub>2</sub> – 5 % CO<sub>2</sub> at room temperature. The composition of the standard solution was (in mM): 119 NaCl, 2.5 KCl, 1.3 MgSO<sub>4</sub>, 2.5 CaCl<sub>2</sub>, 25 Glucose and 26 NaHCO<sub>3</sub>. For recordings Multiclamp 700B amplifier (Molecular Devices) was used together with borosilicate glass pipettes (3–7 MOhm) filled with the following intracellular solution (in mM): 122.5 potassium gluconate, 12.5 KCl, 0.2 EGTA, 10 HEPES, 2 MgATP, 0.3 Na<sub>3</sub>GTP and 8 NaCl adjusted to pH 7.3 with KOH as in (Pfisterer et al., 2011). Data acquisition was performed with pClamp 10.2 (Molecular Devices); current was filtered at 0.1 kHz and digitized at 2kHz. The cells were selected for recording based on their neuronal shape and clear surface, cells with signs of shrinkage or visualized nuclei were excluded. Resting membrane potentials were monitored immediately after breaking-in in current-clamp mode. Thereafter, cells were kept at a membrane potential of -60mV to -70mV, and 500ms currents were injected from -20pA to +90pA with 5pA increments to induce action potentials. For inward sodium and delayed rectifying potassium current measurements cells were clamped at -70mV and voltage-depolarizing steps were delivered for 100ms at 10mV increments. Spontaneous AP were recorded in current-clamp mode at resting membrane potentials. Addition of tetrodotoxin (TTX) to the Krebs solution to final concentration of 1  $\mu$ M was performed in order to specifically block sodium channels and inhibit neuronal activity during recording.

### **Flow cytometry analysis and FACS sorting**

For flow cytometry analysis of the cells between D130-270, the cell clusters were dissociated for 8 min in Accutase (StemPro; Thermo Fisher) and resuspended to 1 million cell/ml in Miltenyi wash buffer (PBS + 0.5% BSA Fraction V + 2  $\mu$ M EDTA + 0.05% Phenol Red). For each staining, 100  $\mu$ l cell suspension was used and the cells were incubated with fluorophore-conjugated antibodies for 15 min at 4°C (PE anti-human CD140a, BD Biosciences, cat. no. 556002, 1:10; APC anti-CD44 (Miltenyi, cat. no. 130-095-177, 1:500); APC anti-human CD133/1, (Miltenyi, cat. no. 130-113-668, 1:50); FITC anti-human SSEA-4, Biolegends, cat. no. 330410, 1:20). Following the 15 min incubation with the antibodies, the cells were washed with Miltenyi wash buffer, centrifuged for 10 min at 200 x g and transferred to 5 ml polystyrene tubes with cell-strainer caps at a final density of around 400,000 cells/ml in DMEM/F12 + DNase. To exclude dead cells, Propidium iodide (PI, Miltenyi, cat. no. 130-095-177, 1:500) was added to the samples. For each sample, 10,000 cells were analyzed on a FACSAria III sorter (BD Biosciences). Gates were set based on Fluorescence Minus One (FMO) controls and compensation was performed using single-stained cells.

For CD140-based cell sorting, the same staining procedure was employed but the cells were stained at a higher density, with the same concentration of CD140a antibody (1:10). To improve the viability of the sorted cells, the sorting medium was supplemented with 10  $\mu$ M Y-27632 and polypropylene tubes that had been precoated with 3.4% BSA Fraction V in PBS overnight were used. The sorted cells were collected in glial medium supplemented with 1x B27 and 10  $\mu$ M Y-27632. For gating strategy for the FACS experiment, see Figure S4.

### **Microscopy**

Fluorescent images were captured using a Leica DMI6000B widefield microscope. The image acquisition software was Leica LAS X and images were processed using Adobe Photoshop CC 2018. Any adjustments were applied equally across the entire image, and without the loss of any information.